The nation of Zimbabwe has rejected a substantial American health deal worth 367 million US dollars (272 million pounds) over five years due to Washington's request for confidential biological samples.
This rejection became public after a government memo dated December was disclosed, revealing that President Emmerson Mnangagwa felt the agreement was "lopsided".
A government representative later clarified that the US was seeking biological samples for research and commercial purposes but was not willing to guarantee the resulting advantages from any future treatments.
"We are forced to start the challenging and unfortunate process of ending our health assistance in Zimbabwe," remarked US ambassador to Zimbabwe Pamela Tremont publicly.
The US Embassy noted the US had provided over $1.9bn for health programmes to Zimbabwe over the last two decades.
A medical body in Zimbabwe has urged more dialogue to reach a agreement suitable to all parties so the nation's vital HIV treatment initiative can continue.
Wider Implications
Zimbabwe's decision comes after a similar case in neighbouring Kenya, where a high court blocked a similar health funding agreement following concerns were filed about the security of citizens' health data.
Since resuming the presidency last year, US President Donald Trump has drastically cut foreign aid and closed the key foreign aid agency.
USAID had administered assistance for the US government, but Trump stated its spending was "inefficient" and his government was pursuing government-to-government agreements to enhance openness and responsibility.
According to reports, Sixteen nations in Africa have so far signed these new health pacts, representing more than $18.3bn of fresh investment.
Details of the Declined Agreement
This assistance for Zimbabwe would have supported "HIV/Aids treatment and prevention, tuberculosis, malaria, healthcare for mothers and children, and preparing for epidemics".
"We believe this collaboration might have yielded immense advantages for Zimbabwean communities, especially the 1.2 million presently on antiretroviral therapy through American-funded programmes," Tremont added.
However, official spokesman Nick Mangwana argued the arrangement was "asymmetrical".
"Zimbabwe was being asked to provide its biological resources and data for a long time, with no equivalent guarantee of benefiting from any scientific breakthroughs – such as new medicines or tests – that could be developed from that provided information," his statement read.
"In essence, our nation would provide the raw materials for medical research without any certainty that the end products would be accessible to our citizens if a future pandemic emerge."
Sovereignty and Global Health
Mangwana further said that the American exit from the World Health Organization (WHO) and its pursuit of bilateral health agreements were disrupting systems already established via the global organization.
Mangwana cited its Pandemic Benefit-Sharing system created to deal with future global health emergencies.
"This system is designed to ensure that when a country contributes its data, the resulting advantages – such as medicines and cures – are distributed fairly, not commercialised solely by those with the resources to develop them."
These objections over the US deal "should not be misconstrued as hostility towards the US," Mangwana stressed.
"We encourage continued discussions with our US partners on how future collaboration might be arranged in a way that respects the independence and dignity of both nations."
Medical Community Reaction
The Zimbabwe College of Public Health Physicians (ZCPHP) expressed it acknowledged the government's concerns, but urged that talks need to persist given that a large portion of the nation's Aids initiatives relied on international support.
"If specific concerns arise, such as those relating to information security or agreement terms, these can often be addressed through technical clarification and negotiated safeguards," it added.
The halted deal underscores the complex debate between receiving much-needed foreign assistance and safeguarding a country's data in an ever more data-driven world.